Univercells, a bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to €50 million financing from Gamma Biosciences, a new investment platform supported by investment firm KKR, that is focused on next generation bioprocessing technologies for the production of advanced biologic therapies including gene and cell-based therapies. The investment will be deployed in a newly created subsidiary of Univercells focuse...